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T-type calcium channels are essential contributors to
the transmission of nociceptive signals in the primary
afferent pain pathway. Here, we show that T-type
calcium channels are ubiquitinated by WWP1, a
plasma-membrane-associated ubiquitin ligase that
binds to the intracellular domain III-IV linker region
of the Cav3.2 T-type channel and modifies specific
lysine residues in this region. A proteomic screen
identified the deubiquitinating enzyme USP5 as a
Cav3.2 III-IV linker interacting partner. Knockdown
of USP5 via shRNA increases Cav3.2 ubiquitina-
tion, decreases Cav3.2 protein levels, and reduces
Cav3.2 whole-cell currents. In vivo knockdown of
USP5 or uncoupling USP5 from native Cav3.2 chan-
nels via intrathecal delivery of Tat peptides mediates
analgesia in both inflammatory and neuropathic
mouse models of mechanical hypersensitivity. Alto-
gether, our experiments reveal a cell signaling
pathway that regulates T-type channel activity and
their role in nociceptive signaling.
INTRODUCTION
Low-voltage-activated T-type calcium channels are important
mediators of electrical signaling in nerve, heart, and smooth
muscle (Chen et al., 2003; Perez-Reyes, 2003; Simms and Zam-
poni, 2014), while their dysfunction has been linked to conditions
such as epilepsy and pain (Bourinet et al., 2014; Simms and
Zamponi, 2014). Vertebrates express three different types of
T-type channels (termed Cav3.1, Cav3.2, and Cav3.3) with spe-
cific expression patterns and unique functional and pharma-
cological profiles (Perez-Reyes, 2003). At the molecular level,
T-type channels are formed by a pore-forming Cav3 subunit
that is comprised of four transmembrane domains that are1144 Neuron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc.connected by cytoplasmic linkers (Perez-Reyes, 2003). These
linker regions contain protein interaction sites and are the targets
of second messengers that modulate T-type channel activity
(Iftinca and Zamponi, 2009).
T-type channels regulate neuronal excitability (Chemin et al.,
2002), and they contribute to low-threshold exocytosis (Weiss
et al., 2012). These important functions are readily apparent in
the primary afferent pain pathway, where T-type channels not
only shape the firing patterns of pain sensing neurons but also
contribute to neurotransmitter release at dorsal horn synapses
(Jacus et al., 2012). Primary afferent pain fibers have their cell
bodies in the dorsal root ganglia (DRG) and express predomi-
nantly the Cav3.2 subtype (for review, see Bourinet et al.,
2014). Knockdown of Cav3.2 via intrathecal (i.t.) delivery of anti-
sense oligonucleotides, or their direct inhibition by small organic
molecules, results in an increase of bothmechanical and thermal
thresholds, thus validating T-type channels as a suitable phar-
macological target (Bourinet et al., 2005; Francois et al., 2013).
T-type currents in primary afferents are enhanced in various
painful pathological conditions, including diabetic neuropathy,
bowel inflammation, and nerve injury (Jagodic et al., 2007;
Marger et al., 2011;Messinger et al., 2009). Themolecular mech-
anisms by which this upregulation occurs are unknown. It is also
not known whether increased T-type channel activity in these
conditions takes place along the afferent fiber, in dorsal horn syn-
apses, or at both loci (Waxman and Zamponi, 2014). Nonethe-
less, preventing this type of enhancement could be a potential
means of combating the development of pain hypersensitivity.
It is well known that ion channel protein levels can be regulated
through ubiquitination by E3 ubiquitin ligases (Altier et al., 2011;
Staub et al., 1996, 1997; Younger et al., 2004). Akin to the rela-
tionship between protein kinases and phosphatases, ubiquitin-
specific proteases (USPs) or deubiquitinases (DUBs) remove
ubiquitin groups from proteins targeted for degradation, leading
to an increase in protein stability (Clague et al., 2013; Komander
et al., 2009). However, their role in ion channel stability has been
virtually unexplored. Here we report the regulation of T-type
channels by a USP, USP5, that binds to and modulates T-type




Figure 1. Neuronal Cav3.2 Channels Are
Ubiquitinated in the Domain III-IV Linker
(A) Western blot of ubiquitinated Cav3.2 channels
immunoprecipitated via the H-300 antibody (Santa
Cruz) from cultured mouse DRG neurons under
control conditions (‘‘C’’) or after preincubation
with 5 mM MG132 (MG) or 100 mM chloroquine
(Chl) overnight, as detected with an anti-ubiquitin
antibody.
(B) Cav3.2 immunoprecipitates from mouse DRG
neurons probed with the H-300 antibody. The
membrane from (A) was stripped and used for re-
probing with the indicated antibody. The lower
panel shows a control blot for a-tubulin using the
same samples as in (A) and (B) but run on a
separate gel. Note that the Cav3.2 band most likely
contains a combination of mono-ubiquitinated
and non-ubiquitinated channels as the addition of
a single ubiquitin molecule adds only 8 kDa.
The blots are representative examples from three
different experiments.
(C) Cav3.2 isoform1 and isoform 2 III-IV linker
sequence alignment for both mouse and human
channels. Arrows indicate lysines and underlined
sequence indicates the PY motif.
(D) Ubiquitin signal of Cav3.2 WT and different
lysine (K1560R, K1576R, K1587R) mutant chan-
nels from tsA-201 cell immunoprecipitates; a
representative blot is shown, n = 4.
(E) Cav3.2 channel immunoprecipitates from
tsA-201 cells of the total pool of channels are
shown by western blot. The membrane from (D)
was stripped and used for reprobing with an anti-
Cav3.2 antibody. A blot for a-tubulin is shown as
control (bottom panel).
(F) Cav3.2 WT and mutant ubiquitinated signals
were quantified by densitometry, normalized as
a ratio of ubiquitinated-Cav3.2 versus a-tubulin,
and expressed as percentage of the control
(WT signal).
See also Figure S1. All error bars reflect standard
errors.
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USP5 Regulation of T-Type ChannelsCav3.2 channels in the afferent pain pathway is regulated by an
interplay of the HECT E3 ligase WWP1 and USP5 that fine tunes
the stability of T-type channel protein in the plasma membrane.
We show that disrupting USP5 regulation increases ubiquitina-
tion and decreases Cav3.2 channel activity, thereby leading to
analgesia in mouse models of inflammatory and neuropathic
pain.
RESULTS
Cav3.2 Ubiquitination in Neurons from Mouse DRG
To determine if T-type channels are subject to ubiquitination,
cultured mouse DRG neurons were harvested in the presence
or the absence of the proteasome inhibitor MG132. Cav3.2 chan-
nels were immunoprecipitated, and western blots were probed
with a ubiquitin-specific antibody. We detected a Cav3.2 ubiqui-
tination signal only from immunoprecipitates from cells treatedNewith 5 mMMG132 but not from cells treated with 100 mM chloro-
quine, a lysosomal inhibitor (Figure 1A), indicating that Cav3.2
channels are ubiquitinated and degraded in the proteasome.
Higher molecular weight bands consistent with channel aggre-
gates were also evident in some of the western blots probed
with a Cav3.2 antibody (Figure 1B; Figure S1 available online),
with these higher molecular weight bands appearing more abun-
dant in MG132-treated cells. Ubiquitination of Cav3.2 channels
was verified by using a different precipitating Cav3.2 antibody
(Figure S1A) and by mass spectrometry analysis (Figures S1B
and S1C). Ubiquitination was also observed with the two other
members of the T-type channel family, Cav3.1 and Cav3.3
(data not shown).
To identify the ubiquitination site in Cav3.2, we focused on the
intracellular domain III-IV linker region of the channel, as this
region includes a number of lysine residues (i.e., the residues





Regulate Cav3.2 Channel Ubiquitination
(A) Western blot of ubiquitinated surface Cav3.2
channels expressed in tsA-201 cells transfected
with WWP1 or WWP2 shRNAs and pretreated with
5 mM MG132 overnight. After biotin labeling of
cells, labeled surface proteins were enriched with
neutravidin beads. Samples were eluted off the
beads with RIPA buffer containing 4M guanidine at
pH 1.6, and samples were tumbled for 30 min at
4C before the samples were dialyzed overnight.
Surface Cav3.2 channels were enriched by immu-
noprecipitation with an anti-Cav3.2 antibody and
probed for ubiquitin.
(B) Western blot of surface pool of Cav3.2 channels
expressed in tsA-201 cells treated with WWP1 or
WWP2 shRNAs.
(C) Western blot of total pool of Cav3.2 channels
expressed in tsA-201 cells treated with WWP1 or
WWP2 shRNAs. An actin blot is shown as sample
control for (A)–(C).
(D) Quantification of ubiquitinated surface Cav3.2
channels by densitometry, normalized as a ratio
of surface ubiquitinated-Cav3.2 versus surface
Cav3.2 (Total Cav3.2), and expressed as percent-
age of the control relative integrated density values
from western blots. Data from three experiments
are included in the bar chart.
(E) Quantification of surface Cav3.2 channels ex-
pressed as the ratio of surface versus total chan-
nels by densitometry to obtain relative integrated
density values from western blots. Data from four
to seven experiments are included in the bar chart.
(F) Affinity purification assays were done using
the following biotinylated peptides; human
Cav3.21556–1602 (long III-IV linker, lane 1) and
Cav3.21569–1586 (short III-IV linker, lane 2) peptides.
Mouse DRG lysates (500 mg) were incubated with
each peptide (50 mg) and neutravidin beads for
2 hr at 4C. Western blot analysis was performed
using rabbit anti-WWP1antibody. A representative
immunoblot is shown (n = 3).
(G) Western blot of Cav3.2 immunoprecipitates
from mouse DRG lysates probed with an anti-
WWP1 antibody.
See also Figure S2. All error bars reflect standard
errors.
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USP5 Regulation of T-Type Channels(PY) HECT E3 ubiquitin ligase binding motif (Staub et al., 1996),
which is conserved in all three Cav3.1, Cav3.2, and Cav3.3 chan-
nels in both human and mouse (Figure 1C). We mutated three
individual lysine residues upstream from the PY motif (i.e.,
K1560R, K1576R, and K1587R) and carried out immunoprecipi-
tations from transfected tsA-201 cells combined with western
blot assays to analyze the effects of the mutations on the ubiqui-
tination level. Ubiquitination of the K1560R and K1576R mutants
decreased by 60% and 25%, respectively, when compared
to wild-type (WT) channels, whereas the K1587Rmutant showed
a similar ubiquitination signal as theWT channel (Figures 1D–1F).
Altogether, these data strongly support the notion that Cav3.2
channels undergo ubiquitinmodification and that the intracellular
III-IV loop is the target for E3 ubiquitin ligases.1146 Neuron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc.Cav3.2 Surface Density Is Regulated by WWP1
and WWP2
We used shRNAs directed against a number of different HECT
E3 ligases, including Nedd4, Nedd4-Long, Itch, Smurf1, Smurf
2, WWP1, and WWP2, and examined their consequences on
ubiquitination of transiently expressed Cav3.2 channels (Fig-
ure 2). tsA-201cells (shRNA treated or untreated) were labeled
with biotin, the labeled surface pool of channels enriched by
immunoprecipitation using a Cav3.2 antibody, and ubiquitina-
tion determined by western blots. Among the various shRNAs
examined, only shWWP1 and shWWP2 mediated a reduction
in ubiquitinated Cav3.2 channels among the Cav3.2 cell surface
pool (to 23% and 25% of control levels, respectively) (Fig-
ures 2A and 2D). The efficiency of WWP1 knockdown was
Neuron
USP5 Regulation of T-Type Channelsverified using western blotting (Figure S2A). Concomitantly,
we observed an 2-fold increase in Cav3.2 cell surface expres-
sion levels when cells were depleted of WWP1 and WWP2
(Figures 2B, 2C, and 2E) but not when cells were treated with
shRNA against Nedd4, an HECT ligase implicated in regulation
of channels such as ENaC (Abriel et al., 1999; Staub et al.,
1996, 1997). Altogether, these data suggest that WWP1 and
WWP2 regulate Cav3.2 cell surface density via ubiquitin
modification.
Next, we tested if WWP1 and WWP2 are able to bind to the
III-IV linker region. We created a 46-amino-acid-long III-IV linker
peptide (hCav3.21556–1602) containing the PYmotif or an 18 amino
acid short peptide lacking the PY motif (hCav3.21569–1586), and
these peptides were then incubated with mouse DRG lysates.
The 46-amino-acid-long peptide encompassing almost the
entire III-IV linker bound WWP1 (104 kDa) (lane 1 in Figure 2F).
In the 18 amino acid peptide lacking the PYmotif, WWP1 binding
was reduced, albeit not completely eliminated (lane 2 in Fig-
ure 2F), suggesting that the PY motif is not the sole determinant
of WWP1 binding. This is confirmed by substitution of the two
tyrosines of the PxYxxY motif with asparagine (Figures S2B
and S2C), which resulted in a partial decrease in their ubiquitina-
tion level (50%) (Figures S2B–S2D).
WWP1 coimmunoprecipitated with Cav3.2 channels in mouse
DRG lysate (Figure 2G), whereas WWP2 did not (Figure S2E).
Control experiments indicate that WWP2 is in fact capable of
interacting with Cav3.2 channels (Figure S2F), but that is only
weakly expressed in DRG neurons (Figure S2G). Altogether,
these data suggest that WWP1 and WWP2 can bind to Cav3.2
and regulate its ubiquitination state.
The DUB USP5 Interacts with Cav3.2 Channels
To determine if the domain III-IV linker interacts with other
components of the ubiquitination machinery, we used a bio-
tinylated version of the highly charged region in the domain
III-IV linker (i.e., residues F1558–R1586) as bait and carried
out affinity precipitation assays followed by mass spectrom-
etry. This yielded several candidate interacting partners (Fig-
ure 3A), including p97 (a protein involved in the proteasomal
degradation pathway) and USP5 (or isopeptidase T), a DUB
recently identified as part of the 26S proteasome (Besche
et al., 2009). We confirmed the Cav3.2-USP5 interaction by
means of affinity precipitation and coimmunoprecipitation as-
says. A biotinylated peptide (which corresponds to residues
1,556–1,602 of the III-IV linker of the human Cav3.2 isoform
2) showed robust binding to USP5 from mouse brain lysate,
whereas a scrambled Cav3.21556–1602 sequence or a Cav3.2
C terminus peptide (corresponding to residues 1,860–1,884
of hCav3.2) did not (Figure 3B). To determine if USP5 binds
to the III-IV linker directly, we carried out in vitro binding as-
says with human recombinant USP5 proteins. As there is evi-
dence of long (858 amino acid) and short (835 amino acid)
USP5 splice isoforms in human tissues (Falquet et al., 1995),
we incubated both recombinant long (96 kDa) and short
(93 kDa) hUSP5 proteins with hCav3.21556–1602 (III-IV linker)
or hCav3.21860–1884 (CT) peptides. Both USP5 isoforms
strongly bound to the Cav3.2 III-IV linker peptide but not to
the Cav3.2 C terminus peptide (Figure 3C), indicating theNeobserved interactions occur independently of USP5 splice
variation.
PCR analysis (Figure S3A) reveals that both USP5 splice iso-
forms are expressed in various regions of the nervous system
that are known to express Cav3.2 channels (Talley et al.,
1999), including cortex, cerebellum, spinal cord, and DRG.
DRG appear to show greater expression of the long form of
USP5, but it is unclear which of the two isoforms is more impor-
tant at the functional level (Figure 3D). Expression of USP5 in
DRG neurons was also verified by immunostaining with a
USP5 antibody (Figure 3E). USP5 expression was observed in
myelinated (i.e., NF200 positive) and to a much lesser degree
in unmyelinated (i.e., IB4 positive) neurons. There was overlap
with markers of peptidergic neurons (Figure S3F). USP5
expression could also be visualized in dorsal horn slices (Fig-
ure 3F). Intense USP5 staining was evident in the nuclei in a
number of neurons (Figures S3B and S3C), which fits with the
well-documented nuclear expression of other types of DUBs
(Clague et al., 2013).
Cav3.2 could be immunoprecipitated with USP5 from mouse
DRG neurons (Figure 3G). Control experiments included Cav3.2-
null mouse DRG tissue and using an additional precipitating
Cav3.2 antibody (Figure 3H). Successful coimmunoprecipitations
were also obtained from mouse dorsal horn lysate (Figure 3I).
Coimmunoprecipitations from whole rat brain further confirmed
the Cav3.2/USP5 interaction, whereas the channels did not coim-
munoprecipitate with USP15, another DUB that is found in brain
(Figures S3D and S3E). Experiments using brain lysate revealed
that Cav3.3 channels weakly interact with USP5, whereas
Cav3.1 channels do not (data not shown).
Overall, these data demonstrate that USP5 binds to the III-IV
linker of Cav3.2 in vitro and binds to the full-length channel in
native tissue.
USP5 Affects Cav3.2 Ubiquitin Modification and T-Type
Channel Activity
To determine if USP5 is able to regulate Cav3.2 channel ubiquiti-
nation, we transfected CAD cells (which express USP5 endoge-
nously) (Figure S4A) with USP5 shRNA. Knockdownwas verified,
and the level of Cav3.2 ubiquitination assessed. Cav3.2 channels
immunoprecipitated from cells transfected with USP5-shRNA
(and treated with 5 mMMG132) exhibited five times greater ubiq-
uitination levels when compared to channels transfected with
USP15-shRNA (Figure S4B). As a result, total Cav3.2 protein
levels were significantly reduced by USP5-shRNA treatment
(Figures S4C and S4D).
We also examined the effects of USP5-shRNA on whole-cell
T-type channel currents in CAD cells. Peak T-type currents
were decreased in CAD cells transfected with USP5-shRNA
(shUSP5: 1.4 ± 0.2 pA/pF, n = 18) when compared with peak cur-
rents obtained from control cells (GFP: 3.3 ± 0.4 pA/pF, n = 20,
Students t test: p < 0.001) (Figures S4E and S4F). Application
of nickel confirmed that the T-type current expressed endoge-
nously in CAD cells was carried by Cav3.2 channels (Figure S4G).
Taken together, these results indicate that ubiquitinated Cav3.2
channels are substrates for USP5 and that the association of
the channel with USP5 results in altered Cav3.2 protein levels




Figure 3. USP5 Interactions with the Cav3.2 III-IV Linker
(A) Interacting proteins from mouse brain lysates that bind to the hCav3.21556–1602-III-IV linker peptide as identified by mass spectrometry.
(B) Affinity purification assays from mouse brain lysate were done using the following biotinylated peptides: scrambled hCav3.21556–1602 (lane 1), human
Cav3.21556–1602(III-IV linker, lane 2), or Cav3.21860–1884 (CT, lane 3) peptides. Western blot analysis was performed using a rabbit antibody to USP5. A blot for actin
is shown as control (bottom panel). A representative immunoblot is shown (n = 3).
(legend continued on next page)
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USP5 Regulation of T-Type ChannelsUSP5 Levels Are Upregulated in Response to Peripheral
Nerve Injury
It is possible that the observed enhancement of T-type channel
activity in various rodent pain models could be due to altered
USP5 regulation.We thus examinedUSP5 levels in DRGand spi-
nal cord tissue from mice that had received an injection of either
PBS or complete Freund’s adjuvant (CFA) into the hindpaw. Tis-
sue was then isolated from the contralateral and ipsilateral side
and analyzed by western blots. As shown in Figure 4, there
was an upregulation of USP5 levels in DRG (Figures 4A and
4B) and spinal dorsal horn (Figures 4C and 4D) tissue on the
ipsilateral side in CFA-treated animals, whereas there was no
change in USP5 levels in tissue isolated from PBS-treated ani-
mals. We also performed similar experiments in mice subjected
to a chronic constriction injury (CCI) of the sciatic nerve. These
experiments revealed that there was an enhanced association
between USP5 and Cav3.2 in the ipsilateral dorsal horn in chron-
ically (14 days after CCI) nerve-injured mice (Figures 4E and 4F).
Along these lines, immunostaining experiments involving spinal
cord slices from mice with a spared nerve injury (SNI) reveal an
increase in USP5 levels in the spinal dorsal horn ipsilateral to
the lesion (Figure 4G).
Altogether, these data fit with a mechanism in which USP5-
mediated regulation of Cav3.2 can occur physically and func-
tionally in both DRG neurons and dorsal horn synapses and is
aberrantly enhanced in chronic pain conditions.
Effect of USP5 Knockdown on Inflammatory Pain
To determine if USP5 could modulate pain signaling via T-type
channels, we treated mice via an i.t. injection of either USP5-
shRNA or USP15-shRNA (both delivered at a dose of 12.5 mg/
i.t. 1 day prior to pain testing). As shown in Figures 5A and 5B,
i.t. delivery of USP5 shRNA resulted in a decrease in USP5 pro-
tein levels in both DRG and dorsal horn tissue and consequently
prevented the upregulation of Cav3.2 channels in animals sub-
jected to CCI (Figure 5C).
To determine whether USP5 modulates afferent pain signaling
under chronic inflammatory processes, we analyzed mechanical
withdrawal threshold of USP5-shRNA-treated animals after
CFA injection. As shown in Figure 5D, mice injected with CFA
developed mechanical hyperalgesia, as indicated by a signifi-
cant decrease of paw withdrawal thresholds (p < 0.001) when
compared to pre-CFA baseline levels of the control group. Three(C) In vitro binding assay of purified recombinant USP5 (long isoform [left] and shor
(CT, lane 3) peptides. The asterisk indicates a degradation product of the USP5 sh
approximately 3 kDa and is not resolved on a nongradient gel.
(D) RT-PCR analysis of USP5 mRNA in different neuronal tissues. The orange bo
(528 bp) USP5 isoforms (n = 3).
(E) Representative example of a mouse DRG slice immunostained for USP5 (1:5
(F) Representative example of USP5 staining of a mouse spinal cord slice colabe
(G) USP5-Cav3.2 coimmunoprecipitation assay using mouse DRG tissue. Cav3.2 i
different immunoprecipitate: the first lane is an IgG control, the second lane reflec
USP5 antibody. A blot for a-tubulin is shown as control (bottom panel). The gel is
(350 kDa) band in the coimmunoprecipitation lane likely reflects an IgG aggreg
(H) Coimmunoprecipitation of USP5 and Cav3.2 from WT and Cav3.2 KO mouse
N terminus (NT) of the channel.
(I) USP5-Cav3.2 coimmunoprecipitation from mouse dorsal horn tissue. Each lan
See also Figure S3.
Nedays after CFA injection, i.t. treatment of mice with USP5-shRNA
(12.5 mg/i.t.) reversed mechanical hyperalgesia induced by CFA
from 9 hr up to 3 days after treatment. In contrast, similar treat-
ment of mice with USP15-shRNAwas ineffective (Figure 5D). We
also tested the role of USP5 in both phases of the formalin model
(Hunskaar and Hole, 1987). A blind analysis demonstrated that
upon USP5-shRNA treatment, the nocifensive response time
(i.e., time spent licking and biting the injected paw) was reduced
by 47%± 7% in the first phase (Figure S5A) and 57%± 5% in the
second phase (Figure S5B).
Collectively, these data indicate that USP5 is a regulator of
chronic pain states accompanying inflammatory processes.
Effect of USP5 Knockdown on Neuropathic Pain
To establish if USP5 also contributes to the development of
neuropathic pain, we examined the prophylactic (1 day before
injury) and therapeutic (12 days after injury) action of USP5-
shRNA in CCI mice. Sciatic nerve constriction triggered both
mechanical (Figure 5E) and thermal (Figure 5F) hyperalgesia,
as indicated by a significant decrease of mechanical and thermal
withdrawal thresholds when compared to pre-CCI baseline
levels of control group (p < 0.01). Treatment of mice with spinal
USP5-shRNA (12.5 mg/i.t., delivered 1 day before nerve injury)
prevented mechanical and thermal hyperalgesia, consistent
with the effects of USP5 shRNA on injury-induced upregulation
of Cav3.2 channels (see Figure 5C). This effect lasted for several
days before returning to control levels at about day 10. Impor-
tantly, a second injection on day 12 reestablished analgesia,
indicating that USP5 knockdown can act both prophylactically
and therapeutically. The second injection of USP5 shRNA ap-
peared less effective than the prophylactic treatment (Figures
5E and 5F), perhaps due to the expression of other plastic
(non-T-type channel-mediated) changes that could occur in
response to injury. Altogether, these data indicate that USP5 is
a major determinant of hypersensitivity in both inflammatory
and neuropathic pain models.
Effect of a Tat-Cav3.2-III-IV Linker Peptide on T-Type
Channel Activity
To determine if the effects of USP5 occurred via Cav3.2 T-type
channels, we designed Tat peptides to competitively disrupt
USP5 binding to the Cav3.2 domain III-IV linker (Figure 6A). We
first verified in an in vitro affinity competition assay that thet isoform [right]) to humanCav3.21556–1602 (III-IV linker, lane 2) or Cav3.21860–1884
ort isoform. The predicted size difference between the long and short isoform is
xes highlight the expected bands for the long (597 bp and 362 bp) and short
00 Ab) and either NCF200 or IB4.
led for USP5 (red) and IB4 (green).
mmunoprecipitates were probed for USP5 by western blot. Each lane reflects a
ts an IP control with a Cav3.2 antibody, and the third lane reflects an IP with the
a representative example from three experiments. The high molecular weight
ate that occasionally appears in co-IPs.
DRG neurons using a Cav3.2 antibody (N18, Santa Cruz) directed against the
e reflects a different immunoprecipitate, as indicated by the small arrows.
uron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc. 1149
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Figure 4. Upregulation of USP5 in Response
to Peripheral Injury
(A) Western blot examining USP5 expression in
mouse L4–L6 DRG tissue isolated ipsilateral or
contralateral to a CFA- or PBS-injected hindpaw
(lane 1: CFA, ipsilateral; lane 2: CFA, contralateral;
lane 3: PBS, ipsilateral; lane 4: PBS, contralateral).
The blot was stained for USP5 and a-tubulin. The
asterisk indicates the USP5 proteolytic fragment
mentioned in Figure 3.
(B) Quantification of a set of experiments such as
that shown in (A) and normalized to a-tubulin. Note
the upregulation of USP5 on the ipsilateral side in
CFA-treated mice.
(C) Experiment analogous to that shown in (A), but
using spinal dorsal horn tissue instead of DRG (and
an actin control rather than a-tubulin).
(D) Quantification of a set of experiments such as
that shown in (C).
(E) Coimmunoprecipitation of Cav3.2 and USP5
from L4–L6 dorsal horn tissue in response to CCI,
indicating an upregulation of the Cav3.2/USP5
interaction on the ipsilateral side of the nerve injury.
(F) Quantification of a set of experiments such as
that shown in (E) relative to actin band intensity.
(G) Representative example of immunostaining of
an L5 mouse dorsal horn slice (14 days after a SNI
of the sciatic nerve) for USP5 (red) and the micro-
glial marker IBA-1 (green). The lower images are a
magnification of the two areas inside the dashed
rectangles. Note the increase in USP5 expression
on the side ipsilateral to the injury.
All error bars reflect standard errors.
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USP5 Regulation of T-Type ChannelsTat-3.2-III-IV peptide was capable of interacting with USP5 (Fig-
ure S6A), and we verified that the Tat peptide did not directly
block Cav3.2 currents in tsA-201 cells (data not shown). We
then tested the effects of the Tat peptides on T-type channel-
mediated calcium entry into acutely dissociated DRG neurons
that were loaded with the calcium indicator dye Fluo-4. After
loading, high-voltage-activated calcium channels were blocked
with 3 mM cadmium, and cells were depolarized with application
of 25 mM KCl to trigger T-type channel-mediated calcium entry
(verified by application of 100 mM nickel, which eliminated
75.3% ± 5.1% [n = 35] of calcium influx). Next, we examined
T-type channel-mediated calcium entry before and after applica-
tion of either the Tat-3.2-III-IV linker peptide or a control Tat pep-
tide directed against the C terminus of the channel. As shown in
Figures 6B and 6C, the former peptide attenuated calcium entry,
whereas the control peptide did not. Altogether, these experi-1150 Neuron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc.ments reveal a USP5-sensitive T-type
calcium current component in DRG cell
bodies, which would be expected to
enhance the excitability of these neurons
(Yue et al., 2013).
T-type channels contribute to sponta-
neous neurotransmitter release in synap-
ses located in laminae I and II of the dorsal
horn, and this contribution is enhanced
under certain chronic pain conditions (Ja-cus et al., 2012). To test if these synaptic T-type channels are
regulated by USP5, we performed miniature excitatory postsyn-
aptic current recordings from spinal cord slices from the lumbar
region (Figures 6D and 6E). Electrodes were placed in lamina II,
which is known to receive inputs from Cav3.2 expressing affer-
ents (Jacus et al., 2012) and includes nerve terminals from
both myelinated and unmyelinated fibers. For each cell, minia-
ture excitatory baseline synaptic activity was recorded, and
then the slice was exposed to 100 mM nickel to determine if syn-
aptic input in a given cell contained a contribution from T-type
channels (Figures 6D and S6B). Nickel was then washed out
and the effects of a subsequent application of the Tat-3.2-III-IV
peptide (10 mg/ml) assessed (Figures 6D and S6C). For 12 out
of 15 cells examined, the application of nickel resulted in a statis-
tically significant increase (p < 0.05, Kolmogorov-Smirnov two-






Figure 5. Nociceptive Response of Mice
Treated with USP5-shRNA
(A) In vivo knockdown of USP5 via i.t. delivery of
shRNA (12.5 mg/i.t.) against USP15 (as a control)
and USP5. L5 DRG were isolated and lysed, and
USP5 immunoprecipitates were probed with an
USP5 antibody. This experiment was repeated
three times. The bar graph represents a quantifi-
cation of the USP5 band intensity relative to the
actin control for three different experiments.
(B) In vivo knockdown of USP5 in dorsal horn tis-
sue via i.t. delivery of shRNA against USP5. The
asterisk denotes the putative USP5 proteolytic
fragment.
(C) Quantification of the effect of USP5-shRNA on
Cav3.2 protein levels in L4–L6 dorsal horn tissue
neurons from mice that were subjected to CCI of
the sciatic nerve. The data were normalized to an
actin control.
(D) Time course of mechanical hyperalgesia of
mice treated with USP5-shRNA or USP15-
shRNA (12.5 mg/i.t.) under CFA-induced chronic
inflammatory pain. Each circle represents the
mean ± SEM (n = 6–8) and is representative of two
independent experiments. Two-way ANOVA re-
vealed that paw withdrawal thresholds of mice
receiving USP5-shRNA were significantly greater
than those treated with USP15-shRNA (negative
control).
(E and F) Time course of mechanical (E) and
thermal (F) hyperalgesia of mice treated with
USP5-shRNA or USP15-shRNA (12.5 mg/i.t.) under
CCI-induced neuropathic pain. Each circle repre-
sents the mean ± SEM (n = 5 to 6) and is repre-
sentative of two independent sets of experiments.
Two-way ANOVA revealed that spinal treatment of
mice with USP5-shRNA significantly attenuated
the mechanical hyperalgesia induced by CCI when
compared with the CCI + USP15-shRNA (control)
group. The dashed line and hashtag indicate the
range of data points where injured animals differed
from the sham treated group (p < 0.001).
See also Figures S4 and S5. All error bars reflect
standard errors.
Neuron
USP5 Regulation of T-Type Channelsinvolvement of T-type channels. One third of the nickel-sensitive
cells displayed a statistically significant increase in interevent in-
terval in response to the Tat-3.2-III-IV peptide (which was quan-
tified and compared to the nonresponders) (Figure 6E). In
contrast, the Tat-3.2-III-IV peptide did not affect the nickel-
insensitive cells. These data indicate that (1) dorsal horn neu-
rons/synapses form a heterogeneous population that differs in
their sensitivities to T-type channel inhibition and (2) there is a
subpopulation of T-type channel-expressing synapses whose
activity is reduced by disruption of the USP5/Cav3.2 channel
interaction.
To determine if USP5 regulation occurs in synaptic nerve ter-
minals from afferent fibers rather than excitatory interneurons,
we examined the effect of the Tat-3.2-III-IV peptide on T-type
channel-mediated events in spinal cord slices evoked by paired
pulse stimulation of the dorsal root entry zone. As shown in Fig-Neures 6F and 6G, the peptide resulted in a statistically significant
increase in paired pulse ratio but not a statistically significant
decrease in evoked EPSC amplitude. Qualitatively similar effects
were observed upon application of 100 mM nickel (Figure S6D).
Altogether, these experiments indicate that USP5 regulation of
Cav3.2 channels occurs both in cell bodies and in synaptic nerve
terminals arising from DRG neurons, which collectively would
result in an enhancement of afferent pain signaling.
Effect of the Tat-Cav3.2-III-IV Linker Peptide on Chronic
Pain Hypersensitivity
We then examined the effects of the III-IV linker Tat peptide (and
as controls, a Tat-free III-IV linker peptide and a Tat peptide
directed against the C terminus of the channel) (see Figure 6A)
in inflammatory (CFA) and neuropathic (CCI) pain models.




Figure 6. USP5 Regulation of Cav3.2 Chan-
nels in DRG Neurons and Dorsal Horn
Synapses
(A) Sequence alignment of peptides used for in vitro
and in vivo mouse studies. Underline indicates a
helix prediction (http://bioinf.cs.ucl.ac.uk).
(B) Examples of calcium fluorescence measure-
ments in acutely dissociated mouse DRG neu-
rons before and after application of either the
Tat-3.2-III-IV or C terminus control peptide (Tat-
3.2-CT) in response to a 25 mM KCl-induced
depolarization.
(C) Bar graph representing a quantification of
the effects of the Tat-3.2-III-IV linker and control
peptides on T-type channel-mediated calcium
rises.
(D) Electrophysiological recordings of miniature
excitatory synaptic events in spinal cord slice re-
cordings from the Substantia gelatinosa in the
absence or presence of either nickel or the Tat-
3.2-III-IV peptide. All traces were taken from the
same nickel-sensitive cell.
(E) Quantification of experiments such as those
shown in (D). The bar graph depicts the effects
of nickel and the Tat-3.2-III-IV peptide on inter-
event interval. Data were normalized to control
and grouped based on statistical analysis
(Kolmogorov-Smirnov two-sample test) of ef-
fects within a given recording (normalized to
control).
(F and G) Effect of the Tat-3.2-III-IV peptide
(10 mg/ml) on evoked synaptic responses in dor-
sal horn neurons. Sample recordings of average
EPSCs in response to paired-pulse stimulations
(100 ms apart, evoked at a rate of 0.2 Hz) before
(baseline; black) and after Tat-3.2-III-IV peptide
(gray) are shown (F). To illustrate effect on
paired pulse ratio (PPR), traces have been
scaled for EPSCs evoked in pulse 1 to be
equivalent in amplitude. Stimulus artifacts have
been cropped for clarity, and scale bars repre-
sent 25 pA and 20 ms. Scatter plots (G) sum-
marize the effect Tat-3.2-III-IV peptide on PPR
(left) and eEPSC amplitude (right) in multiple cells.
Tat-3.2-III-IV peptide significantly increased PPR
(p = 0.02, paired t test) with no concurrent
change in eEPSC amplitude (p = 0.103, paired t test). Black bars are means ± SEM, and black lines between points indicate paired experiments. All
recordings were performed at 70 mV in the continuous presence of 10 mM Cd2+, bicuculline, and 1 mM strychnine.
See also Figures S6 and S7. All error bars reflect standard errors.
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CFA) or CCI-injuredmice (p < 0.01, 5 days after surgery), animals
received a single peptide injection (10 mg/i.t.). i.t. delivery of the
Tat-3.2-III-IV linker peptide significantly (two-way ANOVA) atten-
uated the mechanical hyperalgesia induced by CFA compared
to animals injected with either the C terminus peptide or with
III-IV linker peptides lacking the Tat epitope (Figure 7A). Remark-
ably, the effect of the Tat-3.2- III-IV linker peptide developed
rapidly (over the time course of 30 min) and persisted for up
to 6 hr (Figure 7A).
Next, we determined if the Tat peptide altered endogenous
Cav3.2 protein levels in DRG neurons from CFA-injected mice.
Mice were treated with the Tat-3.2-III-IV linker or the Tat-3.2-
CT peptides 3 days after they had received CFA, and 90 min1152 Neuron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc.later their ipsilateral lumbar (L5) DRG were isolated and Cav3.2
levels analyzed by western blotting (Figures 7B and 7C). We
found that total Cav3.2 levels were reduced by 50% in mDRGs
from CFA-injected mice treated with the Tat-3.2-III-IV linker
peptide (Figure 7C, lane 2) compared with those treated with
Tat-3.2-CT peptide (lane 3) and to levels that were similar to
those seen in altogether naive mice (lane 1). This robust reduc-
tion in total Cav3.2 protein in Tat-3.2-III-IV linker-treated DRG is
consistent with the analgesic effect of the peptide. We note that
there was no direct effect of the peptide on CFA-induced
inflammation per se (i.e., we observed no changes in paw vol-
ume measured via a plethysmometer, paw diameter measured




Figure 7. Antihyperalgesic Effect of the Tat-
Cav3.2-III-IV Linker Peptide inMouseModels
of Chronic Pain
(A) Blind analyses of the time course of mechanical
hyperalgesia of CFA-injected mice treated with
Tat-peptides or control peptides (10.0 mg/i.t.)
compared to the control (intraplantar PBS). Ten
micrograms of peptide correspond to 2.27, 2.22,
and 3.5 nmoles for the Tat-3.2-III-IV, Tat-3.2-CT,
and 3.2-III-IV peptides.
(B) Cav3.2 immunoprecipitates from ipsilateral
lumbar 5 (L5) DRGs from naive mice (lane1), or
fromCFA-injectedmice treated with either Tat-3.2-
III-IV linker (lane2) or Tat-3.2-CT (lane3) peptides,
analyzed bywestern blot 90min after i.t. treatment.
A blot for a-tubulin is shown as control (bottom
panel).
(C) Quantification of Cav3.2 protein levels ex-
pressed as the ratio of Cav3.2 versus a-tubulin by
densitometry.
(D) Time course of mechanical hyperalgesia of
mice treated with either theTat-3.2-III-IV linker or
the Tat-3.2-CT peptides (10.0 mg/i.t.) under CCI-
induced neuropathy.
(E) Effect of the Tat-3.2-CT and Tat-3.2-III-IV
peptides 15 min after i.t. delivery to animals that
subjected to CCI 3 weeks prior to the experiment.
The experimenter was blind to the treatment. In all
panels, each circle/bar represents themean ± SEM
(n = 5–8) and is representative of two independent
sets of experiments. Statistical analyses were
performed by two-way ANOVA followed by a Tu-
key test. The dashed line and hashtag indicate the
range of data points where injured animals differed
from the sham-treated group (p < 0.001).
See also Figures S6 and S7. All error bars reflect
standard errors.
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long-lasting (up to 6 hr) antihyperalgesia when delivered intra-
peritoneally (i.p.) (15 mg/kg) compared to animals treated with
the C terminus control (Figure S7A). The observed time course
fits with observations by other groups that show uptake of Tat
peptides into DRG and spinal cord tissue within 15 min of i.p. de-
livery (Brittain et al., 2011). No differences between Tat-3.2-III-IV
linker and Tat-3.2-CT (control)-treated groups were found in
naive (noninjured) mice (Figure S7B), indicating that the USP5-
mediated regulation of T-type channels occurs only during
chronic pain states and not under basal conditions (in agreement
with Figure 4).
i.t. delivery (10 mg/i.t.) of the Tat-3.2-III-IV linker peptide also
partially reversed mechanical hyperalgesia in CCI-neuropathic
mice (Figure 7D). As in the CFA model, the effects of the peptide
fully developed in less than 1 hr, although the effects did not last
as long in the CCImodel. As shown in Figure 7E, the Tat-3.2-III-IV
peptide was even able the reverse mechanical hyperalgesia un-
der longer term chronic pain conditions (i.e., 3 weeks after CCI)
within 15 min of delivery.
To ensure that the effects of the Tat peptides were specific for
Cav3.2, we carried out a series of experiments in Cav3.2-null
mice. In response to CFA, these mice showed slightly higherNebut not statistically significant mechanical withdrawal thresholds
comparedwithWT animals (Figure 8A). However, the Cav3.2-null
mice were completely insensitive to the Tat-3.2-III-IV linker pep-
tide (Figure 8B). To ensure that the tested Tat peptides were in
fact functional, their activity was verified in WT mice that were
examined on the same day as the knockouts (in a blinded
fashion). We also tested the effects of the Tat peptides in CFA-
treated mice in the presence of the T-type channel blocking
compound mibefradil (i.t.). We first assessed the dose and
time dependence of the effects of mibefradil in CFA-treated
mice to optimize the experimental conditions (data not shown).
We then delivered a maximally effective dose of mibefradil
together with either the Tat-3.2-III-IV or the Tat-3.2-CT peptide
(10 mg i.t.) as a control (Figure 8C). While the Tat-3.2-III-IV pep-
tidemediated a significant reversal of pawwithdrawal thresholds
in vehicle-treatedmice, it did not augment the effects of mibefra-
dil. Altogether, these data suggest that the USP5 mediates its
effect on pain signaling via its action on Cav3.2 channels.
DISCUSSION
Here, we have presented evidence that ubiquitination and deubi-
quitination of Cav3.2 T-type channels is an importanturon 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc. 1153
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Figure 8. Effect of the Tat-Cav3.2-III-IV Linker Peptide on Pain
Behavior of Cav3.2-Null Mice
(A) Baselines andmechanical hyperalgesia ofWT or Cav3.2-null mice following
CFA injection. Each column represents the mean ± SEM (n = 5 to 6) and are
representative of two independent experiments.
(B) Blind analyses of the time course of mechanical hyperalgesia of CFA-in-
jected Cav3.2-null mice treated with the Tat-3.2-III-IV linker or the Tat-3.2-CT
peptides (10.0 mg/i.t.). Each circle represents the mean ± SEM (n = 5–8), and
data are representative of two independent sets of experiments.
(C) Effects of Tat-3.2-III-IV (10.0 mg/i.t.) on mechanical withdrawal threshold
in CFA-injected mice treated with mibefradil (10.0 mg/i.t.). Note the lack of
Tat-3.2-III-IV effect in mibefradil-treated mice. Each circle represents the
mean ± SEM (n = 9–13), and data are representative of two independent sets of
experiments. The experimenter was blinded to the experimental conditions.
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1154 Neuron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc.mechanism for regulation of T-type channel activity in primary
afferent neurons. Our data show that the Cav3.2 domain III-IV
linker is a key regulatory site for channel stability. It interacts
with the E3 ubiquitin ligases of the WWP family and the DUB
USP5 and contains key ubiquitination sites. Hence, the domain
III-IV linker of the channel is a hub for channel regulation that al-
lows for control of channel activity/stability via ubiquitin modifi-
cation (Figure S8). Our data show that WWP1 is able to ubiquiti-
nate the channel, whereas USP5, but not a related DUB USP15,
removes ubiquitin groups from the channel protein. This deubi-
quitination process then results in an increase in whole-cell cur-
rent density, which is expected to be pronociceptive.
Conversely, in vivo knockdown of USP5 with shRNA, or uncou-
pling USP5 from its binding site on the channel via delivery of Tat
peptides, mediated analgesic effects in both inflammatory and
neuropathic pain models. The Tat peptides did not affect basal
nocifensive behavior in naive animals, indicating that under
normal physiological conditions, Cav3.2 channels are either not
regulated by USP5 or that T-type channels do not contribute
significantly to basal nociception.
It is likely that DUBs such as USP5 have many cellular targets
(Komander et al., 2009), which could confound the interpreta-
tions of the in vivo studies, especially those involving USP5
knockdown. However, two lines of experiments support the
idea that USP5 regulates pain via its modulation of T-type
channels. First, uncoupling USP5 from Cav3.2 channels via Tat
peptides directed to specific domain III-IV linker sequences
mediated analgesia that was similar to that observed with
USP5 knockdown. Second, the peptides were completely inef-
fective in Cav3.2 knockout mice and in mice treated with mibe-
fradil. We thus conclude that the pronociceptive effect of USP5
is due to its regulation of T-type channels rather than another
cellular target.
Acute delivery of mibefradil was able to significantly attenuate
mechanical hypersensitivity in the CFA model (see Figure 8C),
consistent with a role of T-type channels in chronic pain condi-
tions. On the other hand, Cav3.2 knockout mice showed a rela-
tively normal withdrawal response to mechanical stimuli in the
CFA model when compared to WT animals. The simplest expla-
nation for this apparent discrepancy is the possible existence of
compensatory mechanisms in the Cav3.2-null mice that maintain
hypersensitivity in response to injury but which are insensitive to
the USP5 interacting III-IV linker Tat peptide.
In principle, T-type channels could contribute to signaling in
afferent fibers via multiple mechanisms, including a contribution
to neuronal firing properties (which fits with the Tat-3.2-III-IV
sensitivity of T-type channel-mediated calcium entry into DRG
cell bodies) and a participation in neurotransmitter release at
dorsal horn synapses. Indeed, a recent study has revealed a
contribution of T-type channels to glutamate release from synap-
tic terminals in dorsal horn lamina I and II and that this effect is
enhanced in a model of diabetic neuropathy (Jacus et al.,
2012). Our observation that the Tat-3.2-III-IV peptide inhibitedStatistical analyseswere performed by two-way or three-way ANOVA followed
by Tukey’s test. The dashed line and hashtag indicate the range of data points
where injured animals differed from the sham-treated group (p < 0.001). All
error bars reflect standard errors.
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in lamina II fits with a mechanism involving a USP5 regulation of
T-type channels at a subset of afferent terminals that contribute
to hypersensitivity. The variability in the observed responses to
nickel and the Tat-3.2-III-IV peptide is not surprising given that
dorsal horn neurons form a highly heterogeneous population
(Graham et al., 2007) that appears to receive inputs from both
T-type channel-expressing and -nonexpressing afferent termi-
nals. While we did not perform an in depth analysis of the coloc-
alization of USP5 and Cav3.2 in specific subsets of neurons, our
observation of preferential expression of USP5 in NF200-posi-
tive neurons (Figure 3E) could suggest that non-nociceptive
fibers are able to trigger nocifensive responses via enhanced
T-type channel activity during inflammatory and neuropathic
pain conditions. Alternatively, it is possible that USP5 expression
profiles in various DRG neuron populations may change in
response to injury. At this point, we cannot rule out the possibility
that Cav3.2 channels might contribute to synaptic inputs from
excitatory interneurons in the dorsal horn and that these termi-
nals are a target for the Tat-3.2-III-IV peptide. However, our
data showing that evoked synaptic events were sensitive to
the Tat-3.2-III-IV peptide support an involvement of synaptic ter-
minals arising from primary afferents. The Tat-3.2-III-IV peptide
also reduced T-type channel-mediated calcium entry into DRG
neuron cell bodies. A USP5-mediated enhancement of Cav3.2
channels in cell bodies and along afferent axons would be pre-
dicted to mediate an enhancement of afferent fiber excitability
(Yue et al., 2013), which could contribute to pain hypersensitivity.
The stability of T-type channels is governed by a balance be-
tween ubiquitin ligase and DUB activity and the rate of degrada-
tion of ubiquitinated channels (Figure S8). Alterations of either
one of these processes in response to nerve injury/inflammation
could give rise to increased T-type channel protein levels in the
plasma membrane. Indeed, knockdown of USP5 or treatment
with the Tat-3.2-III-IV peptide is expected to shift this equilib-
rium to increase the fraction of ubiquitinated channels (note
that the Tat-3.2-III-IV peptide sequence does not include the
PY motif implicated in WWP1 interactions and should thus
selectively uncouple USP5 from the channel). While little is
known about the WWP family of ligases and their regulation,
there is a growing body of literature showing that DUBs are un-
der tight second messenger control and are activated by cellular
pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt that
are upregulated during various pain states (Duan et al., 2012;
Zhang et al., 2012). Our observation showing an enhanced
expression of USP5 and an associated increase in its interaction
with Cav3.2 channels in the ipsilateral dorsal horn of injured
mice may hint at altered transcriptional regulation or trafficking
of USP5 in the primary afferent pain pathway and perhaps in
spinal cord interneurons. Nonetheless, our key finding is that
T-type channel activity can be potently regulated by USP5
and that this regulation can be exploited to mediate analgesia
in different forms of chronic pain.
It is well established the ubiquitination and subsequent pro-
cessing in the endoplasmic-reticulum-associated protein degra-
dation (ERAD) complex is an important quality control mecha-
nism that ensures expression of properly folded proteins
(Ro¨misch, 2005). This type of ubiquitination process is carriedNeout by a large family of endoplasmic reticulum (ER)-localized
E3 ubiquitin ligases. For example, we have recently shown that
Cav1.2 L-type channels are ubiquitinated in the ER and then pro-
cessed in the ERAD complex (Altier et al., 2011). In contrast,
several types of ion channels, including the epithelial sodium
channel ENaC, are ubiquitinated by HECT ubiquitin ligases
such as Nedd4 (Abriel et al., 1999; Staub et al., 1996, 1997)
and then internalized and degraded. Our data show that the
plasma-membrane-localized ubiquitin ligase WWP1 interacts
with Cav3.2 channels in DRG neurons and that knockdown of
WWP1 reduces ubiquitination and cell surface expression of
these channels (see Figure 2). This suggests that Cav3.2 chan-
nels are regulated by ubiquitination directly at the cell surface
similarly to previous observations with ENaC and Nav1.7. The
observation that total protein levels were unaffected by depletion
of WWP1 (Figure 2C) is thus likely due to the fact that less than
10% of Cav3.2 channels in tsA-201 cells are expressed at the
cell surface (I.A.S and G.W.Z., unpublished data). This may
also be true for cultured DRG neurons whose total Cav3.2 pool
was only slightly increased by MG132 treatment (Figure 1B)
even though MG132 stabilized ubiquitinated channels that are
presumably at the plasma membrane. An effect on turnover of
cell surface channels rather than ER export may explain the rapid
time course of the physiological effects of i.t. delivered III-IV
linker Tat peptides. This would not be without precedent, as
USP2-45 has been shown to bind to and regulate ENaC, and
USP10 has been reported to regulate the postendocytic sorting
of CFTR channels (Bomberger et al., 2009; Fakitsas et al., 2007;
Oberfeld et al., 2011; Ruffieux-Daidie´ et al., 2008). The particular
significance of ion channel regulation by ubiquitination for pain
signaling is underscored a recent study showing that reduced
expression of Nedd4-2 in DRG neurons results in increased
Nav1.7 expression and thereby increased pain hypersensitivity
(Cachemaille et al., 2012).
More than 90 different types of deubiquitinating enzymes have
been identified in the humangenomewith varying subcellular dis-
tributions including nuclear, cytoplasmic, and endocytic com-
partments (Nijmanet al., 2005;Urbe´, 2005). Their role in cell phys-
iology has been widely recognized, and they are known to act on
numerous cellular pathways to regulate protein stability and
degradation. DUBs have been suggested as potential drug tar-
gets in a variety of pathological conditions such as cancer,
inflammation, and neurological disorders (Daviet and Colland,
2008; Hussain et al., 2009; Shanmugham and Ovaa, 2008).
Here, we present evidence that DUBsmay also be important reg-
ulators of pain processing in the primary afferent pain pathway by
increasing T-type channel stability, which may open new thera-
peutic approaches for pain management. Disrupting the USP5/
T-type channel interaction for therapeutic purposes would spe-
cifically target a process that is involved in aberrant upregulation
of channel activity, while presumably sparing normal channel
function, thereby reducing the risk of adverse side effects.EXPERIMENTAL PROCEDURES
Detailed methods for spinal cord slice recordings, calcium imagining, electro-
physiology, tissue culture, RT-PCR, immunostaining, and in vivo pain models
are provided as Supplemental Experimental Procedures.uron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc. 1155
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The following drugs were used in the study: formaldehyde, complete
Freund’s adjuvant (CFA), mibefradil (Sigma Chemical Company, Saint Louis),
human biotin-Cav3.21556–1602, biotin-Cav3.21569–1586, scrambled biotin-
Cav3.21556–1602-III-IV linker, biotin-Cav3.21860–1884-CT, Tat-Cav3.21569–1589-III-
IV, no-Tat Cav3.21569–1589-III-IV, Tat-Cav3.2-CT1860–1884, no-Tat-Cav3.2-
CT1860–1884 peptides (Genemed synthesis, Houston), and USP5 and USP15
shRNAs (Thermo Scientific, Open Biosystems). Recombinant long and short
USP5 proteins where purchased from Enzo Life Sciences. When drugs were
delivered by the i.p. route, a constant volume of 10 ml/kg body weight was
injected. When drugs were administered i.t., volumes of between 2–10 ml
were injected in order to adjust the appropriate dose of solution injected.
Appropriate vehicle-treated groups were assessed simultaneously.
Cav3.2 T-Type Channel Antibodies
The following antibodies against Cav3.2 channels were used: H-300 (Santa
Cruz Biotechnologies) is directed against amino acids 2174-2353 in the C ter-
minus region and was used in the majority of our experiments, N-18 (Santa
Cruz Biotechnologies) is directed against the N terminus region, and 555-10
(Novus Biologicals) is an antibody against the domain II-III linker region. No
cross reactivity of the H-300 antibody was observed on western blots for
tsA-201 cell lysate transfected with hCav3.1, and hCav3.3. Cav3.2 was also
immunoprecipitated from WT and Cav3.2-null mouse tissue with the 555-10
antibody and western blots probed with H-300, revealing a specific
(250 kDa) band in WT, but not null, mouse tissue.
Plasmids
Cav3.2 III-IV linker from Cav3.2 full-length EGFP-C1was subcloned into pBlue-
script II KS (+/) using Sal 1 (1.6kb)-BamHI. pBluescript II -Cav3.2 III-IV
linker single mutants K1560R, K1576R, K1587, and Y1594N (human
sequence) were generated by PCR mutagenesis. Cav3.2 III-IV linker mutants
were subcloned into Cav3.2 isoform 2-pcDNA3.1 using Sal1-BamHI. WT
Cav3.2 isoform 2 cDNA was kindly provided by Dr. T. Snutch. Nedd4,
WWP1, and WWP2 shRNA plasmids were purchased from Santa Cruz
Biotechnology, Inc.
Immunoprecipitation and Coimmunoprecipitation Assays
Cells were lysed in RIPA buffer (in mM: 50 Tris, 100 NaCl, 1% Triton X-100, 1%
NP-40, 0.2% SDS, 0.1% Na Deoxycholate, 20 NaF, 10 Na4P2O7 pyrophos-
phate, and 10 EDTA + protease inhibitor cocktail [pH 7.5]). A modified RIPA
buffer (in mM; 50 Tris, 100 NaCl, 0.2% [v/v] Triton X-100, 0.2% [v/v] NP-40,
and 10 EDTA + protease inhibitor cocktail, with or without 5 mM MG132
[pH 7.5]) was used to coimmunoprecipitateCav3.2 channelswithUSP5protein.
Lysates from tsA-201, CAD cells, and rat brain tissue were prepared
by sonicating samples at 60% pulse for 10 s and by centrifugation at
13,000 rpm for 15 min at 4C. Supernatants were transferred to new tubes,
and solubilized proteinswere incubatedwith 50 ml of ProteinG/A beads (Pierce)
and 1 mg of HA antibody (Roche) or 2 mg of anti-Cav3.2 (H-300, Santa Cruz Bio-
technologies, Inc., unless stated otherwise), anti-USP5 (ProteinTech Group,
Inc.), anti-WWP1, anti-WWP2 (Sigma), and anti-USP15 (Abnova) antibodies
overnight while tumbling at 4C. Total inputs were taken from whole-cell sam-
ples representing 4%of total protein and probed for actin. Immunoprecipitates
werewashed twicewith (mM)500NaCl 50Tris (pH7.5) buffer andoncewith 150
NaCl 50 Tris (pH 7.5) buffer, and coimmunoprecipitates were extensively
washed with modified RIPA buffer; beads were aspirated to dryness. Laemmli
buffer was added and samples were incubated at 96C for 7 min. Eluted
samples were loaded on an 8% or 10% Tris-glycine gel and resolved using
SDS-PAGE. Samples were transferred to 0.45 mm polyvinylidenedifluoride
membranes (Millipore), and western blot analysis was performed using an
anti-HA (Covance), anti-Cav3.2 (H-300, Santa Cruz Biotechnologies, Inc.),
anti-ubiquitin (BD PharMingen), anti-actin (Sigma), anti-USP15 (Abnova), anti-
USP5 (ProteinTech Group, Inc.), and anti-tubulin (Abcam) antibodies. Western
blot quantification was performed using densitometry analysis (Quantity One-
BioRad software). Student’s t tests for unpaired data were performed to deter-
mine statistical significance. In each coimmunoprecipitation experiment,
beads-only and IgG controls were performed—for space reasons, such con-
trols were not always included in the figures.1156 Neuron 83, 1144–1158, September 3, 2014 ª2014 Elsevier Inc.Affinity Precipitation of Cav3.2-Interacting Proteins
Total extracts from mouse DRG, dorsal horn, and rat brain were prepared by
centrifugation at 16,100 g for 30 min in buffer containing the following (in
mM): 50 Tris pH 7.6, 150 NaCl, 1% Triton X-100, 1% NP40, 10 EDTA, 10
EGTA, and protease inhibitor cocktail (Roche). Lysates were sonicated at
60% pulse for 25 s, and soluble proteins were collected by centrifugation at
16,100 3 g for 15 min at 4C. Cav3.2-interacting proteins were collected by
incubation with neutravidin-agarose beads (Thermo Scientific) while tumbling
for 2 hr at 4C with human Cav3.21556–1602, Cav3.21860–1884 or scrambled pep-
tide for Cav3.21556–1602 covalently linked to aC-terminal biotin group (Genemed
Synthesis Inc., San Francisco). Protein lysates were also incubated with neu-
travidin beads but no peptide as control. After extensive washing, bound pro-
teins were analyzed by SDS-PAGE and visualized by Coomassie staining.
Visible bands were excised and samples analyzed by MALDI/TOF-MS (Bruker
Instruments Co., Bremen) and Nano-ESI-MS/MS on an API QSTAR-Pulsar
(QSTAR, Applied Biosystems Div., Perkin-Elmer Corp., Foster City).
Pain Models
For the formalin test, animals received 20 ml of 1.25% formalin solution intra-
plantarly (i.pl.) in the ventral surface of the right hindpaw. Animals were
immediately placed individually in observation chambers, and the time spent
licking or biting the injected paw was recorded. A blinded experimenter
observed animals individually from 0–5 min (neurogenic phase) and 15–
30 min (inflammatory phase). To induce inflammatory chronic pain, mice
received 20 ml of Complete Freund’s Adjuvant (CFA) injected subcutaneously
in the plantar surface of the right hindpaw (i.pl.). Control groups received
20 ml of PBS in the ipsilateral paw. Neuropathic pain was induced by loose
ligatures of sciatic nerve. Mice were anaesthetized, and the right sciatic
nerve was exposed at the level of the thigh. Proximal to the sciatic nerve
trifurcation four loose ligatures were loosely tied around so that the epineu-
ral circulation was preserved. In sham-operated mice, the nerve was
exposed but not injured. For additional detail, see Supplemental Experi-
mental Procedures.
Pain Behavioral Assays
Mechanical hyperalgesia wasmeasured using a digital plantar aesthesiometer
(DPA). Animals were placed individually in a small, enclosed testing arena on
top of a wire mesh floor. The DPA device was positioned beneath the animal
so that the filament was directly under the plantar surface of the ipsilateral
hind paw. Each pawwas tested three times per session. Thermal hyperalgesia
was examined by measuring the latency to withdrawal of ipsilateral hind paws
on a focused beam of radiant heat of a Plantar Test apparatus. Animals were
placed individually in a small, enclosed testing arena on top of a wire mesh
floor. The device was positioned beneath the animal so that the radiant heat
was directly under the plantar surface of the ipsilateral hind paw. For additional
detail, see Supplemental Experimental Procedures.
Data Analysis and Statistics
For biochemical and electrophysiological analyses, data values are presented
as mean ± SEM for n experiments. Statistical significance was determined us-
ing Student’s t test unless stated otherwise: *p < 0.05; ** p < 0.01; *** p < 0.001;
NS, statistically not different. For behavioral analyses, data are presented as
means ± SEM and evaluated by one-way, two-way, or three-way ANOVA fol-
lowed by a Tukey’s test. A value of p < 0.05 was considered to be significant.
(*p < 0.05; ** p < 0.01; *** p < 0.001).
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Supplemental Information includes eight figures and Supplemental Experi-
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